Top Story

Novel olaparib combination shows activity in ovarian, breast cancers

May 1, 2015

PHILADELPHIA — A combination treatment composed of the PARP inhibitor olaparib and the investigational PI3K inhibitor BKM120 demonstrated activity and safety for women with triple-negative breast cancer or high-grade serous ovarian cancer, according to study findings presented at the American Association for Cancer Research Annual Meeting.

High-grade serous ovarian cancer and triple-negative breast cancer are similar in that they often have germline BRCA mutations, have a sensitivity to platinum agents and have high copy number alterations based on The Cancer Genome Atlas, according to study background. Further, preclinical data have suggested olaparib (Lynparza, AstraZeneca) is synergistic with BKM120 (Novartis) and BYL719 (Novartis) in both cancers.

In the Journals

High TIL levels predict positive outcomes in HER-2–positive breast cancer

April 30, 2015
High levels of tumor-infiltrating lymphocytes served as an independent positive predictive marker for EFS and pathological complete response in HER-2–positive…
VIDEO: MPDL3280A demonstrates safety, efficacy for patients with metastatic triple-negative breast cancer Meeting News CoverageVideo

VIDEO: MPDL3280A demonstrates safety, efficacy for patients with metastatic triple-negative breast cancer

April 30, 2015
Leisha A. Emens, MD, associate professor of oncology at The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, provides…
Meeting News Coverage

Prolonged overnight fasting may reduce breast cancer risk

April 28, 2015
PHILADELPHIA — Prolonged nighttime fasting may reduce glycemic markers that are associated with an increased risk for breast cancer, according to study results…
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
Video
Immunotherapy trials show renewed application for breast cancer

Immunotherapy trials show renewed application for breast cancer

January 3, 2015
SAN ANTONIO — Douglas Yee, MD, director of the Masonic Cancer Center, as well as professor of medicine and…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage

Novel olaparib combination shows activity in ovarian, breast cancers

May 1, 2015
PHILADELPHIA — A combination treatment composed of the PARP inhibitor olaparib and the investigational PI3K inhibitor BKM120 demonstrated…
In the Journals

High TIL levels predict positive outcomes in HER-2–positive breast cancer

April 30, 2015
High levels of tumor-infiltrating lymphocytes served as an independent positive predictive marker for EFS and pathological complete response in…
VIDEO: MPDL3280A demonstrates safety, efficacy for patients with metastatic triple-negative breast cancer Meeting News CoverageVideo

VIDEO: MPDL3280A demonstrates safety, efficacy for patients with metastatic triple-negative breast cancer

April 30, 2015
Leisha A. Emens, MD, associate professor of oncology at The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer…
Meeting News Coverage

Prolonged overnight fasting may reduce breast cancer risk

April 28, 2015
PHILADELPHIA — Prolonged nighttime fasting may reduce glycemic markers that are associated with an increased risk for breast cancer, according…
Meeting News CoveragePerspective

Black women demonstrate denser breast tissue than white women

April 22, 2015
PHILADELPHIA — Black women exhibited significantly higher breast density than white women in an association that was not explained by BMI and…
Meeting News CoveragePerspective

Breast cancer incidence will increase by 50% by 2030

April 21, 2015
PHILADELPHIA — The total number of invasive and in-situ breast cancer cases in the United States likely will increase 50% by 2030, according to…
Meeting News CoveragePerspective

MPDL3280A shows promise in metastatic triple-negative breast cancer

April 20, 2015
PHILADELPHIA — The investigational immunotherapy MPDL3280A appeared well tolerated and demonstrated favorable efficacy in patients with…
Rowan T. Chlebowski, MD, PhD In the Journals

Hormone therapy affects breast cancer risk differently over time

April 16, 2015
The risk for breast cancer associated with use of menopausal hormone therapy changes over time, according to an analysis of two Women’s Health…
In the Journals

Two-thirds of patients with invasive cancer likely to survive 5 years

April 15, 2015
Two out of three people diagnosed with invasive cancer survive at least 5 years, according to data published in CDC’s Morbidity and Mortality
In the JournalsPerspective

Pathologists concordance rates vary for DCIS, atypia diagnoses

April 14, 2015
Pathologists’ concordance rates for ductal carcinoma in situ and atypical hyperplasia diagnoses were generally lower than their concordance…
More Headlines »
morganatic-roan